drugset / Trial / NCT00861458

Bioavailability Study Of PF-00868554 Administered As 3x250mg Oral Tablets (Wet Granulate, 3x250mg Oral Tablets (Dry Granulate) And 750mg Solution Under Fed State

NCT00861458

Phase 1 Completed 14 enrolled Pfizer
RandomizedSingle-groupOpen-labelBasic science

Summary

This study will test two different formulations. The results will be used to select formulation for phase 3.

Timeline

Start
2009-04
Primary completion
2009-06
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Filibuvir Small molecule 750 mg Oral